- Safety and effectiveness of candesartan and candesartan/HCT fixed dose combination in patients with hypertension. [Multicenter Study]Acta Med Indones 2013; 45(3):193-201AM
- CONCLUSIONS: results of this open observational study showed that candesartan and candesartan/HCT were well tolerated and effective in both treatment-naive patients and uncontrolled hypertensive patients with previous antihypertensive treatment.
- Pharmacokinetic interaction study with fixed high dose combinations of candesartan cilexetil and hydrochlorothiazide. [Randomized Controlled Trial]Int J Clin Pharmacol Ther 2011; 49(12):750-5IJ
- CONCLUSIONS: There was no pharmacokinetic interaction found between the high doses of candesartan 32 mg and HCT 25 mg.
- Phase IV, 8-week, multicenter, randomized, active treatment-controlled, parallel group, efficacy, and tolerability study of high-dose candesartan cilexetil combined with hydrochlorothiazide in Korean adults with stage II hypertension. [Randomized Controlled Trial]Clin Ther 2011; 33(8):1043-56CT
- CONCLUSIONS: The candesartan-HCT combination was associated with a statistically significant lowering of BP compared with candesartan monotherapy. Clinicaltrials.gov: NCT00621153.
- Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy. [Randomized Controlled Trial]Blood Press Suppl 2008; 2:22-30BP
- CONCLUSIONS: Candesartan-HCT 32/12.5 mg and candesartan-HCT 32/25 mg are highly effective and provide improved blood pressure reduction and blood pressure control relative to candesartan 32 mg monotherapy, with maintained tolerability, in hypertensive patients whose blood pressure is not optimally controlled with candesartan monotherapy. Furthermore, candesartan-HCT 32/25 mg is more effective than candesartan-HCT 32/12.5 mg in this population.
- [Effect of candesartan cilexetil with hydrochlorothiazide on blood pressure and ST-segment depression in patients with arterial hypertension]. [Journal Article]Dtsch Med Wochenschr 2007; 132(3):81-6DM
- CONCLUSIONS: Replacing candesartan + hydrochlorothiazide for previously ineffective antihypertensive drugs in patients with uncontrolled arterial hypertension significantly reduced both blood pressure and ST-segment depression during daily life.
- [Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals]. [Randomized Controlled Trial]Arzneimittelforschung 2005; 55(9):505-13A
- CONCLUSIONS: The objectives of the present study were completely met by confirming statistically and clinically the assumption of a clear, long-lasting, safe and metabolically neutral action of CC both for low and high dosages with or without HCT. The intended lowering of blood pressure is effective and well tolerable also repeatedly during the 48-h, therapy-free interval (missed dose trial) which corresponds to a frequent omission of the daily tablet dose and thus well reflects the daily practice in antihypertensive therapeutic regimens.
- AT1-receptor blocker-based combination therapy in hypertension. [Review]Blood Press Suppl 2001; (3):18-25BP
- Despite an increase in the number of patients treated for hypertension, blood pressure control is achieved in a minority of patients. The use of rational, well-tolerated combination regimens with complementary modes of action, such as an AT1-receptor blocker administered with a low dose of a thiazide diuretic, provides an effective and well-tolerated management strategy for patients who require m…
Despite an increase in the number of patients treated for hypertension, blood pressure control is achieved in a minority of patients. The use of rational, well-tolerated combination regimens with complementary modes of action, such as an AT1-receptor blocker administered with a low dose of a thiazide diuretic, provides an effective and well-tolerated management strategy for patients who require more than monotherapy to control blood pressure. In clinical trials in patients with mild-to-moderate hypertension, a newly available combination of candesartan cilexetil-hydrochlorothiazide (HCT) 16/12.5 mg was significantly more effective than either monotherapy. This combination was also more effective than losartan-HCT 50/12.5 mg in two double-blind, randomized studies in patients with mild, moderate or severe hypertension. Furthermore, the antihypertensive efficacy of candesartan cilexetil-HCT was evident at up to 48 h following the last dose, while the effect of losartan-HCT declined rapidly during this period. Thus, the new fixed-dose AT1-receptor blocker/diuretic combination, candesartan cilexetil-HCT 16/12.5 mg combines enhanced efficacy with excellent tolerability and sets a new standard for the treatment of hypertension requiring more than monotherapy.
- Efficacy and tolerability of a combination tablet of candesartan cilexetil and hydrochlorothiazide in insufficiently controlled primary hypertension--comparison with a combination of losartan and hydrochlorothiazide. [Randomized Controlled Trial]Blood Press 2000; 9(4):214-20BP
- This randomized, double-blind study compared the antihypertensive effect, safety and tolerability of a candesartan cilexetil/hydrochlorothiazide (candesartan/HCT; 16/12.5 mg) combination tablet with that of a losartan/HCT (50/12.5 mg) combination tablet in patients with mild-to-moderate primary hypertension insufficiently controlled on previous monotherapy. Men and women, aged 20-80 years, with a…
This randomized, double-blind study compared the antihypertensive effect, safety and tolerability of a candesartan cilexetil/hydrochlorothiazide (candesartan/HCT; 16/12.5 mg) combination tablet with that of a losartan/HCT (50/12.5 mg) combination tablet in patients with mild-to-moderate primary hypertension insufficiently controlled on previous monotherapy. Men and women, aged 20-80 years, with a sitting diastolic blood pressure (DBP) > or = 90 and < or = 110 mmHg and sitting systolic blood pressure (SBP) < or = 200 mmHg during treatment with any kind of antihypertensive monotherapy for at least 4 weeks were randomized to candesartan/HCT or losartan/HCT once daily for 12 weeks. All BP measurements were performed 24 h after previous dose. Mean values and standard deviations (SD) or confidence intervals (CI) are given. A total of 340 patients were enrolled, of whom 299 (144 women and 155 men, mean age 59.5 [10.5] years) were randomized to candesartan/HCT (n = 151) or losartan/HCT (n = 148). BPs at randomization were 159.5 (15.4)/98.4 (5.8)mmHg and 160.5 (16.1)/98.5 (5.4)mmHg, respectively. There was a greater reduction in BP with candesartan/HCT than with losartan/HCT: DBP -10.4 (-11.8; -8.9) vs -7.8 (-9.3; -6.3) mmHg, difference between treatments -2.6 (-4.7; -0.5) mmHg (p = 0.016); SBP -19.4 (-22.1; -16.7) vs - 13.7 (-16.5; - 10.9) mmHg, difference between treatments -5.7 (-9.6; -1.8) mmHg (p = 0.004). The proportion of patients achieving a DBP < or = 90 mmHg was greater in the candesartan/HCT group: 60.9 (53.1; 68.7) vs 49.3 (41.3; 57.4)% (p = 0.044). There were 12 withdrawals in the candesartan/HCT group, of which 8 were due to adverse events, and 17 and 12, respectively in the losartan/HCT group. We conclude that the combination of candesartan and HCT reduces BP effectively and is well tolerated. BP was normalized in 61% of these patients who had insufficient response to previous monotherapy. The reduction in BP and the proportion of patients with normalized BP were greater with the candesartan/HCT 16/12.5 mg combination than with the losartan/ HCT 50/12.5 mg combination.